Early interleukin-6 receptor inhibition with tocilizumab safely suppressed systemic inflammation but did not reduce peak NT-proBNP or left ventricular infarct size in patients with acute myocardial infarction (AMI) at increased risk of cardiogenic shock (CS), according to new data from the DOBERMANN-T trial.